Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-10-08, Stock:ABBV, The news for the past five days is as follows:
2021-10-01: NEWS1: Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More.
2021-10-04: NEWS1: AbbVie (ABBV) Stock Moves -0.33%: What You Should Know.NEWS2: Botox war: East Bay challenger sued by maker of blockbuster cosmetic toxin.NEWS3: Investing in Pharma Stocks? Watch for These 2 Red Flags.
2021-10-05: NEWS1: AbbVie to Host Third-Quarter 2021 Earnings Conference Call.
2021-10-06: NEWS1: Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations.
2021-10-07: NEWS1: Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis.NEWS2: AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis.NEWS3: Why AbbVie Stock Sank in September.NEWS4: 10 Dividend Stocks to Increase Your Monthly Income.NEWS5: AbbVie Higher on Rinvoq Trial Progress to Treat Spinal Arthritis.NEWS6: AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.NEWS7: AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis.

Answer: Rise